목적 : 자궁경부암의 종양표지물질로 쓰이는 SCC의 병기 및 조직학적 분류에 따른 양성율, 치료 후의 혈중농도를 알아보고 보조적 종양표지물질로 흔히 쓰이는 CEA와 CA-125의 병기 및 조직학적 분류에 따른 양성율을 알아보고자 본 연구를 시도하였다. 연구 방법 : 1997년 1월 초부터 2001년 12월 말까지 고려대학교 의과대학 안암병원 산부인과 부인암 크리닉에서 병리조직학적 검사에서 자궁경부암으로 진단 받은 환자들 중에서 치료 전에 혈중 SCC, CEA 및 CA- 125가 측정된 환자 222명을 대상으로 하였다. 결과 : 222명의 자궁경부암 환자에서 종양 표지물질인 SCC, CEA, CA-125의 양성율은 각각 38.7%, 24.3%, 19.8%였다. 임상병기에 따른 각각의 양성율은 SCC의 경우 제I기가 12.9%, 제II기가 60.5%, 제III기가 88.2%, 제IV기가 87.5%, CEA의 경우 제I기 7.8%, 제II기 36.4%, 제III기가 46.2%, 제IV기가 71.4%, CA-125의 경우 제I기가 5.9%, 제II기가 23.3%, 제III기가 83.3%, 제IV기가 75%로 세 경우 모두에서 임상병기가 증가될수록 양성율이 증가하는 경향을 보였다 (p<0.05). 조직학적 분류에 따라서는 편평상피암에서 SCC가 양성률 39.8%로 CEA나 CA-125보다 의미있게 높은 양성율을 보였고, 선암이나 선편평상피암에서는 CA-125가 다소 높은 양성율을 보였으나 통계적으로 의미있는 차이를 보이지는 않았다. 결론 : 자궁경부암의 종양 표지 물질로는 SCC가 다른 표지물질보다 양성율이 높았다. SCC, CEA, CA- 125의 양성율은 임상병기가 진행될수록 높았으며, SCC 단독 측정보다는 CEA, CA-125를 함께 측정하는 것이 더 유용할 것으로 생각되며 이에 대해 향후 더 많은 연구가 필요하다.

Objective : The aim of this study was to evaluate the positive rate of squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA), and CA-125 according to clinical stage and histology. We also determine the rate of normalization of SCC after surgical and radiation therapy. Results : In 222 patients with cervical cancer, the pre-treatment positive rate of SCC, CEA, and CA- 125 were 38.7%, 24.3%, and 19.8%, respectively. The positive rate of SCC by clinical stage were 12.9% for stage I, 60.5% for stage II, 88.2% for stage III, and 87.5% for stage IV. The positive rate of CEA by stage were 7.8% for stage I, 36.4% for stage II, 83.3% for stage III, and 75% for stage IV. The positive rate of CA-125 by stage were 5.9% for stage I, 23.3% for stage II, 83.3% for stage III, and 75% for stage IV. The positive rates of SCC, CEA, and CA-125 were significantly increased by clinical stage. According to histology, the positive rate of SCC (39.8%) was more significantly higher than the positive rates of other tumor makers in squamous cell carcinoma of the uterine cervix. The positive rate of CA-125 was higher than the positive rate of other tumor markers in adenocarcinoma and adenosquamous carcinoma of the uterine cervix, but it was not statistically significant difference. Conclusion : SCC have been shown to be higher positive rate than any other tumor markers in patients with cervical cancer. The positive rates of SCC, CEA, and CA-125 were significantly increased by clinical stage. Concomitant measurement of SCC, CEA, and CA-125 may be more useful than measurement of SCC alone, and further study was needed.

Objective : The aim of this study was to evaluate the positive rate of squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA), and CA-125 according to clinical stage and histology. We also determine the rate of normalization of SCC after surgical and radiation therapy. Results : In 222 patients with cervical cancer, the pre-treatment positive rate of SCC, CEA, and CA- 125 were 38.7%, 24.3%, and 19.8%, respectively. The positive rate of SCC by clinical stage were 12.9% for stage I, 60.5% for stage II, 88.2% for stage III, and 87.5% for stage IV. The positive rate of CEA by stage were 7.8% for stage I, 36.4% for stage II, 83.3% for stage III, and 75% for stage IV. The positive rate of CA-125 by stage were 5.9% for stage I, 23.3% for stage II, 83.3% for stage III, and 75% for stage IV. The positive rates of SCC, CEA, and CA-125 were significantly increased by clinical stage. According to histology, the positive rate of SCC (39.8%) was more significantly higher than the positive rates of other tumor makers in squamous cell carcinoma of the uterine cervix. The positive rate of CA-125 was higher than the positive rate of other tumor markers in adenocarcinoma and adenosquamous carcinoma of the uterine cervix, but it was not statistically significant difference. Conclusion : SCC have been shown to be higher positive rate than any other tumor markers in patients with cervical cancer. The positive rates of SCC, CEA, and CA-125 were significantly increased by clinical stage. Concomitant measurement of SCC, CEA, and CA-125 may be more useful than measurement of SCC alone, and further study was needed.

Cervical squamous cell carcinoma, Cervical adenocarcinoma, SCC, CEA, CA-125